Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

1(33.3%)

Phase 1

1(33.3%)

Phase 3

1(33.3%)

3Total

N/A(1)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03649503Recruiting

The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China

Role: collaborator

NCT04694495Completed

HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study

Role: collaborator

NCT04287660Phase 3Unknown

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Role: collaborator

NCT04284150Not ApplicableUnknown

Treatment of Supraventricular Tachycardia in Patients With Non-cardiac Surgery by Dexmedetomidine

Role: lead

NCT02848794Phase 1Unknown

Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma

Role: collaborator

All 5 trials loaded